Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomodulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.
【저자키워드】 COVID-19, SARS-CoV-2, Inflammation, Atherosclerosis, anti-inflammatory treatment, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, coronavirus, Mortality, cardiovascular system, severe acute respiratory syndrome Coronavirus, Venous Thromboembolism, immunomodulator, immunomodulators, myocardial injury, myocarditis, Atherosclerosis, excess mortality, endothelial injury, disease, Arrhythmias, anti-inflammatory agents, inflammatory pathways, heart disease, similarity, reduction, Cardiovascular events, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, atherosclerotic, systemic inflammatory response, thrombotic, similarities, severe complications, thrombotic event, atherosclerotic heart disease, caused, involved, cardiovascular event, inflammatory pathway, 【제목키워드】 pharmaceutical, current,